Median age at SCT (range) | 53.6 years old (18–69) |
Median follow-up (range) | 21 months (3.3–146) |
Interval between diagnosis and CR1 (range) | 56.5 days (18–170) |
Intervals from CR1 to SCT (range) | 81.5 days (11–286) |
Median year of SCT | 2009 (2000–2013) |
Secondary AML, N (%) | 19 (15.2%) |
CMV+ patient, N (%) | 84 (68.3%) |
CMV+ donor, N (%) | 65 (68.3%) |
Karnofsky >90% at SCT, N (%) | 83 (70.3%) |
Gender, N (%) | |
Male | 71 (57%) |
Female | 54 (43%) |
Donor type, N (%) | |
Sibling | 60 (48%) |
Unrelated | 54 (43.2%) |
Cord blood | 10 (8%) |
Source of SC, N (%) | |
BM | 19 (15.2%) |
PB | 95 (76%) |
CB | 10 (8%) |
Conditioning regimen, N (%) | |
MAC | 51 (41%) |
RIC | 73 (59%) |
In vivo T cell depletion, N (%) | 64 (51%) |
ATG | 47 (38%) |
Alemtuzumab | 17 (14%) |
Monosomal karyotype, N (%) | 86 (82.7%) |
Missing, N | 21 |
Complex karyotype, N (%) | 98 (90.7%) |
Missing, N | 17 |
Inv(3), N (%) | 3 (2.9%) |
Missing, N | 20 |
-7, N (%) | 41 (39%) |
Missing, N | 20 |
-5/5q-, N (%) | 58 (55.2%) |
Missing, N | 20 |
Both -7 and -5/5q-, N (%) | 28 (26.9%) |